Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01528046 · ClinicalTrials.gov registry record · Phase 1
Metformin in Children With Relapsed or Refractory Solid Tumors
A Phase 1 study, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01528046 is a Phase 1 study that has completed, run by H. Lee Moffitt Cancer Center and Research Institute. The registered enrollment target is 26 participants.
The verdict
NCT01528046, a Phase 1 study, has completed, sponsored by H. Lee Moffitt Cancer Center and Research Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.
Interventions
- DRUG Temozolomide
- DRUG Metformin
- DRUG Vincristine
- DRUG Irinotecan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2012-09-24 |
| Est. Completion | 2020-02-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01528046
The ClinicalTrials.gov registry entry for NCT01528046 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lee Moffitt Cancer Center and Research Institute, which has 502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Temozolomide is the first listed.
NCT01528046 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01528046 about?
NCT01528046 is a clinical study titled "Metformin in Children With Relapsed or Refractory Solid Tumors". The purpose of this study is to evaluate the tolerability and safety of escalating doses of metformin on a backbone of vincristine, irinotecan and temozolomide (VIT) in children with recurrent and refractory solid tumors.
What is the current status of trial NCT01528046?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2012-09-24. Estimated completion is 2020-02-03.
What interventions are being tested in trial NCT01528046?
The interventions under investigation include: Temozolomide (DRUG), Metformin (DRUG), Vincristine (DRUG), Irinotecan (DRUG).
Who is sponsoring clinical trial NCT01528046?
This trial is sponsored by H. Lee Moffitt Cancer Center and Research Institute, which has 502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.